.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
US Army
Covington
Dow
Citi
Colorcon
Boehringer Ingelheim
Chubb
Baxter
Deloitte

Generated: November 25, 2017

DrugPatentWatch Database Preview

Levocarnitine - Generic Drug Details

« Back to Dashboard

What are the generic sources for levocarnitine and what is the scope of levocarnitine patent protection?

Levocarnitine
is the generic ingredient in three branded drugs marketed by Leadiant Biosci Inc, Lyne, Impax Labs Inc, Luitpold, West-ward Pharms Int, Teva Pharms Usa, and Hi Tech Pharma, and is included in nine NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Levocarnitine has four patent family members in four countries.

There are four drug master file entries for levocarnitine. Five suppliers are listed for this compound.

Pharmacology for levocarnitine

Ingredient-typeCarnitine
Drug ClassCarnitine Analog
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hi Tech Pharma
LEVOCARNITINE
levocarnitine
SOLUTION;ORAL077399-001Oct 25, 2007AARXNoNo► Subscribe► Subscribe► Subscribe
Leadiant Biosci Inc
CARNITOR
levocarnitine
INJECTABLE;INJECTION020182-001Dec 16, 1992APRXYesYes► Subscribe► Subscribe ► Subscribe
Leadiant Biosci Inc
CARNITOR
levocarnitine
SOLUTION;ORAL018948-002Apr 27, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Leadiant Biosci Inc
CARNITOR
levocarnitine
INJECTABLE;INJECTION020182-001Dec 16, 1992APRXYesYes► Subscribe► Subscribe ► Subscribe
Luitpold
LEVOCARNITINE
levocarnitine
INJECTABLE;INJECTION075861-001Jun 22, 2001APRXNoNo► Subscribe► Subscribe► Subscribe
West-ward Pharms Int
LEVOCARNITINE
levocarnitine
INJECTABLE;INJECTION075567-001Mar 29, 2001APRXNoNo► Subscribe► Subscribe► Subscribe
Leadiant Biosci Inc
CARNITOR SF
levocarnitine
SOLUTION;ORAL019257-002Mar 28, 2007AARXYesNo► Subscribe► Subscribe► Subscribe
Leadiant Biosci Inc
CARNITOR
levocarnitine
INJECTABLE;INJECTION020182-001Dec 16, 1992APRXYesYes► Subscribe► Subscribe ► Subscribe
Lyne
LEVOCARNITINE
levocarnitine
SOLUTION;ORAL076851-001Aug 10, 2004AARXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
LEVOCARNITINE
levocarnitine
INJECTABLE;INJECTION075881-001Mar 29, 2001DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: levocarnitine

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,914,076 Treating chronic uremic patients undergoing periodical dialysis► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: levocarnitine

Country Document Number Estimated Expiration
Australia3050201► Subscribe
World Intellectual Property Organization (WIPO)0152836► Subscribe
European Patent Office1257266► Subscribe
Canada2381187► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
UBS
Dow
Covington
Cantor Fitzgerald
McKinsey
AstraZeneca
US Army
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot